Eddie Hickman
Stock Analyst at Guggenheim
(4.40)
# 1,196
Out of 4,520 analysts
45
Total ratings
62.5%
Success rate
26.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Downgraded: Hold | n/a | $7.22 | - | 3 | Jul 16, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $90 | $59.85 | +50.38% | 15 | Jul 14, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | $25 → $29 | $12.77 | +127.09% | 7 | Jun 9, 2026 | |
| GHRS GH Research | Maintained: Buy | $29 → $34 | $28.71 | +18.43% | 4 | Mar 9, 2026 | |
| PMN ProMIS Neurosciences | Maintained: Buy | $125 → $35 | $15.19 | +130.41% | 4 | Feb 5, 2026 | |
| HELP Cybin | Maintained: Buy | $39 → $48 | $7.25 | +562.07% | 3 | Dec 3, 2025 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $1.39 | - | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $40.26 | +9.29% | 2 | Aug 11, 2025 |
AtaiBeckley
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.22
Upside: -
Tarsus Pharmaceuticals
Jul 14, 2026
Reiterated: Buy
Price Target: $90
Current: $59.85
Upside: +50.38%
Zevra Therapeutics
Jun 9, 2026
Maintained: Buy
Price Target: $25 → $29
Current: $12.77
Upside: +127.09%
GH Research
Mar 9, 2026
Maintained: Buy
Price Target: $29 → $34
Current: $28.71
Upside: +18.43%
ProMIS Neurosciences
Feb 5, 2026
Maintained: Buy
Price Target: $125 → $35
Current: $15.19
Upside: +130.41%
Cybin
Dec 3, 2025
Maintained: Buy
Price Target: $39 → $48
Current: $7.25
Upside: +562.07%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.39
Upside: -
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $40.26
Upside: +9.29%